Abstract
The clinical use of Botulinum toxin (BoTx) in motor paralytic disorders until now is limited to spasticity relief in isolated spastic muscle/s. This paper advocates that BoTx should be used as a neuro-relearning tool that can significantly improve recovery in motor paralytic disorders. BoTx generates redundant numbers of synapses at motor endplates and at spinal motoneuron-interneurons. It facilitates muscle activity-dependent synapse competition at these two sites. Redundancy and competition-based selection of synaptic connections are naturally occurring learning- related plasticity events during infant motor learning- now familiarly known as competitive-learning. Thus when injected in small doses to multiple muscles of a paralyzed limb, BoTx can recreate and replay those competitive-learning processes in the learningresistant paralyzed brain centers. Computational modeling, humanoid robot, and animal studies reveal that motor re) learning can be significantly faster if competitive-learning mechanisms are employed in the paralyzed system. A treatment protocol is presented that aims to keep the paralyzing effects of BoTx minimized while prolonging relearning duration. Recent clinical studies strongly attest that small-dose; multi-muscle, repeat regimens improve function. The principal objective of the present paper is that future multi-muscle clinical studies will take note of the relearning properties of BoTx and make full utilization of this therapeutic effect.
Keywords: Botulinum toxin, cerebral palsy, motor paralysis, spinal cord injury, stroke, traumatic brain injury (TBI)
Current Drug Therapy
Title: Botulinum Toxin as a Neuro-Relearning Drug Tool in Motor Paralytic Disorders
Volume: 4 Issue: 2
Author(s): R. Venkata Krishnan
Affiliation:
Keywords: Botulinum toxin, cerebral palsy, motor paralysis, spinal cord injury, stroke, traumatic brain injury (TBI)
Abstract: The clinical use of Botulinum toxin (BoTx) in motor paralytic disorders until now is limited to spasticity relief in isolated spastic muscle/s. This paper advocates that BoTx should be used as a neuro-relearning tool that can significantly improve recovery in motor paralytic disorders. BoTx generates redundant numbers of synapses at motor endplates and at spinal motoneuron-interneurons. It facilitates muscle activity-dependent synapse competition at these two sites. Redundancy and competition-based selection of synaptic connections are naturally occurring learning- related plasticity events during infant motor learning- now familiarly known as competitive-learning. Thus when injected in small doses to multiple muscles of a paralyzed limb, BoTx can recreate and replay those competitive-learning processes in the learningresistant paralyzed brain centers. Computational modeling, humanoid robot, and animal studies reveal that motor re) learning can be significantly faster if competitive-learning mechanisms are employed in the paralyzed system. A treatment protocol is presented that aims to keep the paralyzing effects of BoTx minimized while prolonging relearning duration. Recent clinical studies strongly attest that small-dose; multi-muscle, repeat regimens improve function. The principal objective of the present paper is that future multi-muscle clinical studies will take note of the relearning properties of BoTx and make full utilization of this therapeutic effect.
Export Options
About this article
Cite this article as:
Krishnan Venkata R., Botulinum Toxin as a Neuro-Relearning Drug Tool in Motor Paralytic Disorders, Current Drug Therapy 2009; 4 (2) . https://dx.doi.org/10.2174/157488509788185169
DOI https://dx.doi.org/10.2174/157488509788185169 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease
Current Neuropharmacology Oxidative Stress in the ICU
Current Nutrition & Food Science An Overview on the Role of α -Synuclein in Experimental Models of Parkinson’s Disease from Pathogenesis to Therapeutics
CNS & Neurological Disorders - Drug Targets Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation
Current Neuropharmacology A Focus on the Synthesis and Pharmacokinetics of Tocainide and its Analogues
Current Medicinal Chemistry Lifestyle, Maternal Nutrition and Healthy Pregnancy
Current Vascular Pharmacology GSK-3 Inhibitors: A New Class of Drugs for Alzheimer’s Disease Treatment
Current Drug Targets Calpain as a Potential Therapeutic Target in Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Designing Peptide Mimetics for the Treatment of Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry Dementia Etiologies and Remedies in Traditional Persian Medicine; A Review of Medicinal Plants and Phytochemistry
Current Drug Metabolism Formulation Development of Chitosan Coated Intra Nasal Ropinirole Nanoemulsion for Better Management Option of Parkinson: An In Vitro Ex Vivo Evaluation
Current Nanoscience α-Synuclein- and MPTP-Generated Rodent Models of Parkinsons Disease and the Study of Extracellular Striatal Dopamine Dynamics: A Microdialysis Approach
CNS & Neurological Disorders - Drug Targets Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) MAP Segmentation of Time-Frequency Rényi Entropy - Application in Seismic Signals Processing
Recent Patents on Signal Processing (Discontinued) Positron Emission Tomography and Brain Monoamine Neurotransmission - Entries for Study of Drug Interactions
Current Pharmaceutical Design Influence of Essential Trace Minerals and Micronutrient Insufficiencies on Harmful Metal Overload in a Mongolian Patient with Multiple Sclerosis
Current Aging Science Antiglucocorticoids, Neurogenesis and Depression
Mini-Reviews in Medicinal Chemistry